188 related articles for article (PubMed ID: 11504819)
1. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
2. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
3. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
7. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
8. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
9. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
10. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
[TBL] [Abstract][Full Text] [Related]
11. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulatory DNA activates production of type I interferons and interleukin-6 in equine peripheral blood mononuclear cells in vitro.
Wattrang E; Berg M; Magnusson M
Vet Immunol Immunopathol; 2005 Sep; 107(3-4):265-79. PubMed ID: 15955566
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic effect of CpG DNA mediated by type I IFN.
Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides.
Mannon RB; Nataraj C; Pisetsky DS
Cell Immunol; 2000 Apr; 201(1):14-21. PubMed ID: 10805969
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA.
Kim D; Rhee JW; Kwon S; Sohn WJ; Lee Y; Kim DW; Kim DS; Kwon HJ
Biochem Biophys Res Commun; 2009 Feb; 379(2):362-7. PubMed ID: 19103173
[TBL] [Abstract][Full Text] [Related]
17. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
18. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes.
Roberts TL; Dunn JA; Sweet MJ; Hume DA; Stacey KJ
Mol Immunol; 2011 Apr; 48(8):1027-34. PubMed ID: 21324527
[TBL] [Abstract][Full Text] [Related]
19. Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice.
Matheu V; Treschow A; Teige I; Navikas V; Issazadeh-Navikas S
Respir Res; 2005 Mar; 6(1):25. PubMed ID: 15748290
[TBL] [Abstract][Full Text] [Related]
20. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs.
Kim D; Jung J; Lee Y; Kwon HJ
Mol Immunol; 2011 Jul; 48(12-13):1494-504. PubMed ID: 21529949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]